天麻素通过激活AMPK信号通路改善非酒精性脂肪性肝病
本研究探讨天麻素对NASH的治疗作用及机制。在高脂或高脂高胆固醇饮食喂养小鼠及原代小鼠和人类肝细胞系中,天麻素显著减轻肝脏脂质蓄积、炎症和纤维化相关通路,且对主要器官影响小;机制上通过激活AMPK通路,AMPK抑制剂或敲低可阻断其保护作用。
要点
- 天麻素在体内外均显著改善NASH模型中的脂质蓄积和炎症反应
- 天麻素通过激活AMPK通路发挥肝脏保护作用
- AMPK抑制剂Compound C或AMPK敲低可阻断天麻素的保护效应
核心结论
- 天麻素通过激活AMPK通路减轻脂肪性肝炎,有望成为治疗NASH的药物。
研究设计与样本
- 研究采用高脂饮食或高脂高胆固醇饮食喂养的小鼠模型,以及原代小鼠肝细胞和人类肝细胞系进行体内外实验。
主要发现
- 与相应溶剂对照组相比,天麻素治疗显著降低高脂或高脂高胆固醇饮食小鼠的肝脏重量、肝脏和血清甘油三酯及胆固醇含量、血清丙氨酸氨基转移酶和天冬氨酸氨基转移酶活性。
- 天麻素对小鼠其他主要器官的功能和组织学特征影响极小。
- 在原代小鼠肝细胞和人类肝细胞系中,天麻素显著减少代谢应激下的脂质蓄积和炎症反应。
- RNA测序分析表明天麻素抑制NASH发病中与脂质蓄积、炎症和纤维化相关的通路及关键调节因子。
- 机制上,AMPK抑制剂Compound C或AMPK敲低阻断了天麻素介导的肝脏保护效应。
临床怎么用
- 天麻素可能作为NASH的潜在治疗药物,其作用依赖于AMPK通路的激活。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: NASH is currently one of the most common causes of liver transplantation and hepatocellular carcinoma. Thus far, there is still no effective pharmacological therapy for this disease. Recently, Gastrodin has demonstrated hepatoprotective effects in a variety of liver diseases. The aim of this study is to investigate the function of Gastrodin in NASH. APPROACH AND RESULTS: In our study, Gastrodin showed potent therapeutic effects on NASH both in vivo and in vitro. In high-fat diet or high-fat and high-cholesterol diet-fed mice, the liver weight, hepatic and serum triglyceride and cholesterol contents, and serum alanine aminotransferase and aspartate aminotransferase activity levels were markedly reduced by Gastrodin treatment as compared with the corresponding vehicle groups. Notably, Gastrodin showed minimal effects on the function and histological characteristics of other major organs in mice. We further examined the effects of Gastrodin on lipid accumulation in primary mouse hepatocytes and human hepatocyte cell line and observed that Gastrodin showed a significant decrease in lipid accumulation and inflammatory response in hepatocytes under metabolic stress. Furthermore, RNA-sequencing analysis systemically indicated that Gastrodin suppressed the pathway and key regulators related to lipid accumulation, inflammation, and fibrosis in the pathogenesis of NASH. Mechanistically, we found that Gastrodin protected against NASH by activating the adenosine monophosphate-activated protein kinase (AMPK) pathway, which was supported by the result that the AMPK inhibitor Compound C or AMPK knockdown blocked the Gastrodin-mediated hepatoprotective effect. CONCLUSIONS: Gastrodin attenuates steatohepatitis by activating the AMPK pathway and represents a therapeutic for the treatment of NASH.
引用
- Wan J, Zhang Y, Yang D, et al. Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway. Hepatology. 2021. PMID: 34297426. doi:10.1002/hep.32068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。